Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer - PubMed

14 hours ago

Connective Tissue Growth Factor (CTGF) is identified as a key factor in resistance to anti-angiogenic therapies (AATs) in clear cell renal cell carcinoma (ccRCC).
CTGF, regulated by the YAP in the Hippo pathway, promotes tumor progression, angiogenesis, and fibrosis, contributing to AAT resistance.
Elevated CTGF levels in ccRCC patients correlate with shorter progression-free survival, suggesting its role as a predictive biomarker.
The study suggests CTGF inhibition as a potential strategy to overcome AAT resistance and improve treatment outcomes in ccRCC.

Hasty Briefsbeta